2019
DOI: 10.5812/ijcm.84627
|View full text |Cite
|
Sign up to set email alerts
|

Metabolic Syndrome and Risk of Colorectal Cancer: A Case-Control Study

Abstract: Background: Among Middle East countries, the prevalence of Metabolic Syndrome (MetS) and Type 2 Diabetes Mellitus (T2DM) dramatically increased in Iran. Very few evidence-based studies have been performed on the relationship between metabolic disorders and colorectal cancer (CRC) in developing countries at least in Iran. Objectives: This case-control study aimed to determine the relationship between MetS and CRC risk. Methods: A case-control study with 414 participants (207 cases and 207 controls) was conducte… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 27 publications
0
3
0
Order By: Relevance
“…MetS is also associated with cancer (in particular breast, endometrial, prostate, pancreatic, hepatic, colorectal, and renal), 236–238 as well as with gastroenteropancreatic neuroendocrine tumors. 239…”
Section: Complicationsmentioning
confidence: 99%
“…MetS is also associated with cancer (in particular breast, endometrial, prostate, pancreatic, hepatic, colorectal, and renal), 236–238 as well as with gastroenteropancreatic neuroendocrine tumors. 239…”
Section: Complicationsmentioning
confidence: 99%
“…MetS is also associated with cancer (in particular breast, endometrial, prostate, pancreatic, hepatic, colorectal, and renal cancer), 236–238 as well as with gastroenteropancreatic neuroendocrine tumors. 239 A nationwide cohort study conducted among Korean individuals studied the changes in MetS status and breast cancer risk and found that compared with the sustained non-MetS group, the adjusted HR for breast cancer was 1.11 (95% CI, 1.04–1.19) in the transition to MetS group, 1.05 (95% CI, 0.96–1.14) in the transition to non-MetS group, and 1.18 (95% CI, 1.12–1.25) in the sustained MetS group.…”
Section: Metabolic Syndromementioning
confidence: 99%
“…MetS is also associated with breast, endometrial, prostate, pancreatic, hepatic, colorectal, and renal cancers, 236–238 as well as with gastroenteropancreatic neuroendocrine tumors. 239 A nationwide cohort study conducted among Korean individuals found that, compared with the sustained non-MetS group, the aHR for breast cancer was 1.11 (95% CI, 1.04–1.19) in the transition to MetS group, 1.05 (95% CI, 0.96–1.14) in the transition to non-MetS group, and 1.18 (95% CI, 1.12–1.25) in the sustained MetS group.…”
Section: Metabolic Syndromementioning
confidence: 99%